Compare JYNT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JYNT | MOLN |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.7M | 103.5M |
| IPO Year | 2014 | 2021 |
| Metric | JYNT | MOLN |
|---|---|---|
| Price | $6.21 | $2.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.00 | ★ $9.97 |
| AVG Volume (30 Days) | ★ 63.8K | 1.7K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $117,696,356.00 | N/A |
| Revenue This Year | $5.87 | N/A |
| Revenue Next Year | $0.18 | N/A |
| P/E Ratio | $49.62 | ★ N/A |
| Revenue Growth | ★ 15.49 | N/A |
| 52 Week Low | $6.42 | $2.63 |
| 52 Week High | $10.67 | $5.36 |
| Indicator | JYNT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 26.89 |
| Support Level | N/A | N/A |
| Resistance Level | $9.49 | $4.21 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 2.49 | 0.41 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.